1. Scrip
  2. >>Business

Agios CEO Fouse On Building A Sustainable Business Model

 
• By Jessica Merrill

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

new direction
Agios is going in a new direction when it comes to early R&D • Source: Shutterstock (Shutterstock)

Having shifted its commercial and research focus from cancer to non-cancer hemolytic rare diseases last year, Agios Pharmaceuticals, Inc. is now paring back on drug discovery research to focus on advancing a later-stage portfolio of drugs, including potentially ones that will be externally sourced. It's a significant change for a company that was initially established in 2008 as a drug discovery company, but CEO Jackie Fouse said it is all part of an evolution to develop a sustainable business model and tap current market opportunities.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.